Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL AUTISM THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL AUTISM THERAPY MARKETSIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL AUTISM THERAPY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL AUTISM THERAPY MARKET, BY TYPE
17.1 OVERVIEW
17.2 BEHAVIORAL THERAPY
17.2.1 APPLIED BEHAVIOR ANALYSIS (ABA)
17.2.2 COGNITIVE BEHAVIORAL THERAPY (CBT)
17.2.3 PIVOTAL RESPONSE TREATMENT (PRT)
17.2.4 EARLY INTENSIVE BEHAVIORAL INTERVENTION (EIBI)
17.3 OCCUPATIONAL THERAPY
17.3.1 SENSORY INTEGRATION THERAPY
17.3.2 FINE MOTOR SKILLS TRAINING
17.3.3 ACTIVITIES OF DAILY LIVING (ADLS) TRAINING
17.3.4 PLAY-BASED THERAPY
17.4 SPEECH THERAPY
17.4.1 LANGUAGE DEVELOPMENT
17.4.2 SOCIAL COMMUNICATION INTERVENTIONS
17.4.3 PICTURE EXCHANGE COMMUNICATION SYSTEM (PECS)
17.4.4 ASSISTIVE COMMUNICATION DEVICES (E.G., AAC DEVICES)
17.5 PHYSICAL THERAPY
17.5.1 GROSS MOTOR SKILL DEVELOPMENT
17.5.2 BALANCE AND COORDINATION TRAINING
17.5.3 MUSCLE STRENGTHENING
17.5.4 POSTURAL TRAINING
17.6 SOCIAL SKILLS TRAINING
17.6.1 GROUP SOCIAL SKILLS PROGRAMS
17.6.2 PEER INTERACTION PROGRAMS
17.6.3 EMOTIONAL REGULATION TRAINING
17.7 SENSORY INTEGRATION THERAPY
17.7.1 AUDITORY INTEGRATION THERAPY
17.7.2 VISUAL INTEGRATION THERAPY
17.7.3 TACTILE STIMULATION PROGRAMS
17.8 COGNITIVE THERAPY
17.8.1 COGNITIVE DEVELOPMENT INTERVENTIONS
17.8.2 MINDFULNESS-BASED COGNITIVE THERAPY (MBCT)
17.8.3 EXECUTIVE FUNCTION TRAINING
17.9 DEVELOPMENTAL THERAPY
17.9.1 DEVELOPMENTAL, INDIVIDUAL DIFFERENCES, RELATIONSHIP-BASED MODEL (DIR)
17.9.2 FLOORTIME THERAPY
17.9.3 RELATIONSHIP DEVELOPMENT INTERVENTION (RDI)
17.1 MEDICATIONS
17.10.1 ANTIPSYCHOTIC MEDICATIONS
17.10.1.1. RISPERIDONE
17.10.1.2. ARIPIPRAZOLE
17.10.2 ANTIDEPRESSANTS
17.10.2.1. SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)
17.10.2.2. TRICYCLIC ANTIDEPRESSANTS (TCAS)
17.10.3 STIMULANTS
17.10.3.1. METHYLPHENIDATE
17.10.3.2. AMPHETAMINE-BASED MEDICATIONS
17.10.4 ANTI-ANXIETY MEDICATIONS
17.10.5 ANTICONVULSANTS
18 GLOBAL AUTISM THERAPY MARKET, BY DELIVERY MODE
18.1 OVERVIEW
18.2 IN-PERSON THERAPY
18.2.1 ONE-ON-ONE SESSIONS
18.2.2 GROUP THERAPY
18.3 HOME-BASED THERAPY
18.3.1 PARENT-LED PROGRAMS
18.3.2 HOME VISITING SPECIALISTS
18.4 TELEHEALTH THERAPY
18.4.1 VIRTUAL BEHAVIORAL THERAPY
18.4.2 ONLINE SPEECH THERAPY
18.4.3 REMOTE SOCIAL SKILLS TRAINING
18.5 SCHOOL-BASED THERAPY
18.5.1 INDIVIDUALIZED EDUCATION PROGRAM (IEP) SUPPORT
18.5.2 CLASSROOM-BASED SUPPORT SERVICES
18.6 COMMUNITY-BASED THERAPY
18.6.1 RECREATIONAL THERAPY PROGRAMS
18.6.2 AFTER-SCHOOL SOCIAL PROGRAMS
19 GLOBAL AUTISM THERAPY MARKET, BY AGE GROUP
19.1 OVERVIEW
19.2 CHILDREN
19.3 ADOLESCENTS
19.4 ADULTS
20 GLOBAL AUTISM THERAPY MARKET, BY END USER
20.1 OVERVIEW
20.2 THERAPY CENTERS
20.3 HOSPITALS
20.4 HOME CARE SETTINGS
20.5 SCHOOLS AND EDUCATIONAL INSTITUTIONS
20.6 RESEARCH INSTITUTES
20.7 REHABILITATION CENTERS
20.8 COMMUNITY CENTERS
21 GLOBAL AUTISM THERAPY MARKET, BY REGION
21.1 GLOBAL AUTISM THERAPY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
21.1.1 NORTH AMERICA
21.1.1.1. U.S.
21.1.1.2. CANADA
21.1.1.3. MEXICO
21.1.2 EUROPE
21.1.2.1. GERMANY
21.1.2.2. FRANCE
21.1.2.3. U.K.
21.1.2.4. NORWAY
21.1.2.5. POLAND
21.1.2.6. ITALY
21.1.2.7. SPAIN
21.1.2.8. RUSSIA
21.1.2.9. TURKEY
21.1.2.10. NETHERLANDS
21.1.2.11. SWITZERLAND
21.1.2.12. REST OF EUROPE
21.1.3 ASIA-PACIFIC
21.1.3.1. JAPAN
21.1.3.2. CHINA
21.1.3.3. SOUTH KOREA
21.1.3.4. INDIA
21.1.3.5. AUSTRALIA
21.1.3.6. SINGAPORE
21.1.3.7. THAILAND
21.1.3.8. MALAYSIA
21.1.3.9. INDONESIA
21.1.3.10. PHILIPPINES
21.1.3.11. VIETNAM
21.1.3.12. REST OF ASIA-PACIFIC
21.1.4 SOUTH AMERICA
21.1.4.1. BRAZIL
21.1.4.2. ARGENTINA
21.1.4.3. PERU
21.1.4.4. REST OF SOUTH AMERICA
21.1.5 MIDDLE EAST AND AFRICA
21.1.5.1. SOUTH AFRICA
21.1.5.2. SAUDI ARABIA
21.1.5.3. UAE
21.1.5.4. EGYPT
21.1.5.5. KUWAIT
21.1.5.6. ISRAEL
21.1.5.7. REST OF MIDDLE EAST AND AFRICA
21.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
22 GLOBAL AUTISM THERAPY MARKET, SWOT AND DBMR ANALYSIS
23 GLOBAL AUTISM THERAPY MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 NEW PRODUCT DEVELOPMENT & APPROVALS
23.7 EXPANSIONS
23.8 REGULATORY CHANGES
23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL AUTISM THERAPY MARKET, COMPANY PROFILE
24.1 CENTRIA HEALTHCARE
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 THE AUTISM COMMUNITY NETWORK (ACN)
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 AUTISM LEARNING PARTNERS
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 THE CENTER FOR AUTISM AND RELATED DISORDERS (CARD)
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 HOPEBRIDGE AUTISM THERAPY CENTERS
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 EASTERSEALS
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 AUTISM SPEAKS
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 TRUMPET BEHAVIORAL HEALTH
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 BLUESPRIG PEDIATRICS
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 AVEANNA HEALTHCARE
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 BEHAVIOR FRONTIERS
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 MAGELLAN HEALTH
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 THERAPLAY, INC.
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 ACHIEVE BEYOND
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 LITTLE LEAVES BEHAVIORAL SERVICES
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 NEW ENGLAND ABA
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 MELMARK
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
24.18 THE LOVAAS INSTITUTE
24.18.1 COMPANY OVERVIEW
24.18.2 REVENUE ANALYSIS
24.18.3 GEOGRAPHIC PRESENCE
24.18.4 PRODUCT PORTFOLIO
24.18.5 RECENT DEVELOPMENTS
24.19 AUTISM CARE PARTNERS
24.19.1 COMPANY OVERVIEW
24.19.2 REVENUE ANALYSIS
24.19.3 GEOGRAPHIC PRESENCE
24.19.4 PRODUCT PORTFOLIO
24.19.5 RECENT DEVELOPMENTS
24.2 THERAPIES 4 KIDS
24.20.1 COMPANY OVERVIEW
24.20.2 REVENUE ANALYSIS
24.20.3 GEOGRAPHIC PRESENCE
24.20.4 PRODUCT PORTFOLIO
24.20.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
